Intellia's Lonvo-z Nears FDA Review with Strong HAE Data
Event summary
- Lonvo-z Phase 3 HAELO trial met all primary and secondary endpoints, reducing attacks by 87% vs. placebo.
- FDA BLA submission for lonvo-z expected in second half of 2026 with U.S. launch planned for first half of 2027.
- Nex-z Phase 3 trials resumed enrollment; MAGNITUDE-2 completion anticipated by year-end.
- $195M capital raise in April 2026 boosts cash position to $628M, funding operations into 2028.
The big picture
Intellia's positive Phase 3 data for lonvo-z positions it as a potential first-to-market CRISPR-based therapy for hereditary angioedema. The company's strong cash position and resumed nex-z trials reflect strategic momentum in gene editing, though execution risks remain around regulatory approvals and commercialization timing.
What we're watching
- Regulatory Timing
- Whether FDA will accept lonvo-z BLA submission in second half of 2026 and complete review by first half 2027 launch.
- Commercial Readiness
- The pace at which Intellia can scale commercial operations for lonvo-z ahead of potential approval.
- Pipeline Progress
- How genomic insights from nex-z trials will impact ATTR amyloidosis treatment development.